{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=8&state=Wisconsin",
    "query": {
      "state": "Wisconsin",
      "city": "Milwaukee",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 5340,
    "total_pages": 534,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=9&state=Wisconsin&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=7&state=Wisconsin&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T12:18:15.671Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00612742",
      "title": "Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypoactive Sexual Desire Disorder"
      ],
      "interventions": [
        {
          "name": "testosterone gel",
          "type": "DRUG"
        },
        {
          "name": "placebo gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioSante Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 3656,
      "start_date": "2008-01",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 141,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00612742"
    },
    {
      "nct_id": "NCT01281254",
      "title": "AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "AMG386 plus PLD",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus PLD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 223,
      "start_date": "2011-04-18",
      "completion_date": "2017-04-19",
      "has_results": false,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01281254"
    },
    {
      "nct_id": "NCT03207256",
      "title": "Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "TGR-1202",
          "type": "DRUG"
        },
        {
          "name": "TGR-1202 + Ublituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 51,
      "start_date": "2017-08-09",
      "completion_date": "2022-06-24",
      "has_results": false,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 17,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207256"
    },
    {
      "nct_id": "NCT03465722",
      "title": "(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "GIST"
      ],
      "interventions": [
        {
          "name": "avapritinib",
          "type": "DRUG"
        },
        {
          "name": "regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 476,
      "start_date": "2018-03-26",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2022-10-06",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Santa Monica, California • Aurora, Colorado + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03465722"
    },
    {
      "nct_id": "NCT02082353",
      "title": "Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Granulomatous Disease, Chronic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1480,
      "start_date": "2014-06",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2021-09-02",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02082353"
    },
    {
      "nct_id": "NCT03346070",
      "title": "Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neuromuscular Blockade"
      ],
      "interventions": [
        {
          "name": "Sugammadex 2 mg/kg ABW",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 2 mg/kg IBW",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 4 mg/kg ABW",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 4 mg/kg IBW",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine + Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Rocuronium or Vecuronium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2018-01-01",
      "completion_date": "2019-01-29",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 13,
      "location_summary": "Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03346070"
    },
    {
      "nct_id": "NCT00811473",
      "title": "Pediatric Bipolar Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Depression"
      ],
      "interventions": [
        {
          "name": "Quetiapine XR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 193,
      "start_date": "2009-01",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-07-15",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 31,
      "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811473"
    },
    {
      "nct_id": "NCT01874353",
      "title": "Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Platinum Sensitive",
        "BRCA Mutated",
        "Relapsed Ovarian Cancer",
        "Following Complete or Partial Response to Platinum Based Chemotherapy"
      ],
      "interventions": [
        {
          "name": "Olaparib 300mg tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match olaparib 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 327,
      "start_date": "2013-09-03",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01874353"
    },
    {
      "nct_id": "NCT00036712",
      "title": "Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neuroblastoma",
        "Oral Complications",
        "Ovarian Cancer",
        "Pain",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "pain therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 80,
      "start_date": "2002-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036712"
    },
    {
      "nct_id": "NCT00706654",
      "title": "Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Aripiprazole depot 300 or 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole 10-30 mg orally",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole depot 25 or 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo depot",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 937,
      "start_date": "2008-09-01",
      "completion_date": "2012-08-01",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-18T12:18:15.671Z",
      "location_count": 39,
      "location_summary": "Cerritos, California • Escondido, California • Garden Grove, California + 31 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00706654"
    }
  ]
}